GYKI 52466
GYKI 52466[edit | edit source]
GYKI 52466 is a chemical compound known for its role as a non-competitive AMPA receptor antagonist. It is primarily used in neuroscience research to study the effects of AMPA receptor inhibition on synaptic transmission and neuroprotection.
Mechanism of Action[edit | edit source]
GYKI 52466 functions by binding to the AMPA receptor, a type of ionotropic glutamate receptor in the central nervous system. Unlike competitive antagonists, GYKI 52466 does not compete with glutamate for binding at the receptor's active site. Instead, it binds to an allosteric site, causing a conformational change that reduces the receptor's activity. This non-competitive inhibition results in decreased excitatory synaptic transmission, which can be beneficial in conditions characterized by excessive neuronal excitation.
Applications in Research[edit | edit source]
In neuroscience research, GYKI 52466 is utilized to explore the role of AMPA receptors in various physiological and pathological processes. It has been instrumental in studies investigating epilepsy, ischemic stroke, and neurodegenerative diseases such as Alzheimer's disease. By inhibiting AMPA receptor activity, researchers can assess the contribution of these receptors to neuronal excitotoxicity and cell death.
Potential Therapeutic Uses[edit | edit source]
The neuroprotective properties of GYKI 52466 have sparked interest in its potential therapeutic applications. In preclinical models, it has shown promise in reducing neuronal damage following ischemic events and in mitigating seizure activity. However, further research is needed to evaluate its safety and efficacy in humans.
Chemical Properties[edit | edit source]
GYKI 52466 is a member of the 2,3-benzodiazepine family, characterized by its unique chemical structure that allows for selective inhibition of AMPA receptors. The compound's structure is depicted in the accompanying image, highlighting its distinct molecular configuration.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
